Trial completion date • Trial termination • Trial primary completion date • Combination therapy
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ALK rearrangement • ROS1 rearrangement • EGFR rearrangement
|
Opdivo (nivolumab) • marrow infiltrating lymphocytes